Supernus Pharmaceuticals, Inc. SUPN
At closeNov 3, 2026, 5:34 PM EST
After hours · Nov 3, 5:34 PM ET
- YTD
- -43.36%
- 1 year
- -49.46%
- Market cap
- 1.64B
- Revenue (ttm)
- 865.11M
- Profit margin
- -5.07%
- EPS (ttm)
- -0.76
- Shares out
- 58.24M
- Forward P/E
- 6.75
- YTD return
- -43.36%
- 1-year return
- -49.46%
- Volume
- 7.82M
- Avg volume
- 850.44K
- Open
- 28.35
- Previous close
- 28.15
- Day's range
- 27.97 – 31.62
- 52-week range
- 27.97 – 59.68
- Beta
- 0.52
- Analysts
- Strong Buy
- Price target
- 60.50 (+114.9%)
- Earnings date
- Feb 23, 2027
2Y -6.55 (-18.88%)
Key statistics
- Enterprise value
- 2.12B
- PEG ratio
- 0.00
- Price / sales
- 1.89
- Price / book
- 1.54
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 18.00%
- Free cash flow
- 61.71M
- Total cash
- 359.46M
- Total debt
- 36.20M
- Return on equity
- -4.15%
- Short % of float
- 8.51%
- 50-day average
- 42.42
- 200-day average
- 47.25
Analyst view
Consensus: strong buy
- Target (low)
- 55.00
- Target (mean)
- 60.50
- Target (high)
- 67.00
- Strong buy0
- Buy3
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate 1.04.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 30, 2026 | 1.03 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 0.49 | 0.35 | -0.14 | -28.57% |
| Aug 3, 2026 | Jun 30, 2026 | 0.4225 | 0.54 | +0.12 | +27.81% |
| May 5, 2026 | Mar 31, 2026 | 0.28 | 0.59 | +0.31 | +110.71% |
| Feb 24, 2026 | Dec 31, 2025 | 0.28 | 0.92 | +0.64 | +228.57% |
| Nov 4, 2025 | Sep 30, 2025 | 0.82 | 1.01 | +0.19 | +23.17% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 9, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Dec 19, 2025 | Stifel | main | Hold | Hold |
| Oct 29, 2025 | B of A Securities | init | — | Buy |
| Oct 23, 2025 | TD Cowen | main | Buy | Buy |
| Oct 9, 2025 | Piper Sandler | up | Neutral | Overweight |
| Sep 30, 2025 | Cantor Fitzgerald | main | Overweight | Overweight |
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia in patients with Parkinson's disease (PD) receiving levodopa/carbidopa; Oxtellar XR, an extended-release oxcarbazepine product indicated for monotherapy for partial-onset seizures; ZURZUVAE, a neuroactive steroid with GABAergic activity, for the treatment of postpartum depression (PPD) in adults; and APOKYN for the acute, intermittent treatment of hypomobility or off-episodes in patients with advanced PD. It also provides Trokendi XR, an extended-release topiramate product indicated for the treatment of epilepsy and for migraine prophylaxis; XADAGO for use with levodopa/carbidopa in patients with PD experiencing off-episodes; and MYOBLOC, a type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor in a Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in a Phase 2 clinical trial for treatment-resistant depression; and SPN-443, a stimulant in a Phase 1 trial for the treatment of ADHD and other CNS conditions. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of a Phase 2 clinical program for SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland. As of November 2, 2026, Supernus Pharmaceuticals, Inc. operates as a subsidiary of Indivior Pharmaceuticals, Inc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- supernus.com
News
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader 
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript 
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates 
Supernus Pharmaceuticals Q3 Earnings Call Highlights 
Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript 
Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript 
Supernus Pharmaceuticals Raises FY2026 Sales Guidance from $860.000M-$890.000M to $875.000M-$900.000M vs $877.738M Est 
Supernus Pharmaceuticals Q3 EPS $0.35 Beats $0.02 Estimate, Sales $226.771M Beat $215.917M Estimate 
Supernus Announces Third Quarter 2026 Financial Results
Your note
Sign in to keep a note on SUPN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARLOW CARROLEE | Director | Stock Award(Grant) | Feb 23, 2026 | 27,045 |
| BHATT PADMANABH P | Officer | Conversion of Exercise of derivative security | Aug 11, 2026 | 18,637 |
| DEC TIMOTHY C | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 11, 2026 | 9,129 |
| GEMAYEL GEORGES PH.D. | Director | Sale | Mar 5, 2026 | 27,277 |
| HUDSON FREDERICK M | Director | Sale | Mar 11, 2026 | 60,413 |
| KHATTAR JACK A | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 11, 2026 | 2,216,450 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.06% | 9,350,046 | 263.20M | Jun 29, 2026 |
| Millennium Management Llc | 6.62% | 3,853,212 | 108.47M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.68% | 3,305,429 | 93.05M | Jun 29, 2026 |
| Armistice Capital, LLC | 4.54% | 2,646,201 | 74.49M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.32% | 2,516,721 | 70.85M | Jun 29, 2026 |
| State Street Corporation | 4.22% | 2,459,828 | 69.24M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.94% | 3,460,493 | 97.41M | Sep 29, 2026 |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 3.29% | 1,917,295 | 53.97M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 1,750,148 | 49.27M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.48% | 1,445,625 | 40.69M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.17% | 1,263,284 | 35.56M | Jun 29, 2026 |
| Vanguard Explorer Fund | 1.49% | 870,341 | 24.50M | Jul 30, 2026 |